Work

Trial in progress: A phase Ib study of AMG 510, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in patients with advanced solid tumors harboring KRAS p.G12C mutation (CodeBreak 101).

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.15_suppl.tps3661

Authors: Marwan Fakih, Greg Andrew Durm, Ramaswamy Govindan, Gerald Steven Falchook, Neelesh Soman, Haby Adel Henary, David S. Hong

Institutions: City Of Hope National Medical Center, Indiana University Health, Indiana University Indianapolis, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Washington University in St. Louis, The University of Texas MD Anderson Cancer Center

Language: English

Topic: Protein Kinase Regulation and GTPase Signaling

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Amgen

OpenAlex ID: W3032409113

Cites:

Cited by: 9

Related to: 10